What the label actually says The Mounjaro and Zepbound prescribing information states: "Available data with tirzepatide use in pregnant women are insufficient to evaluate for a drug-related risk of major birth defects, miscarriage, or other adverse maternal or fetal outcomes." The label then references animal studies: "Based on animal reproduction studies, there may be risks to the fetus from exposure to tirzepatide during pregnancy." And the recommendation: "Advise pregnant women of the potential risk to a fetus
(1) Prevention from DPP-4 degradation
For Eli Lilly, Mounjaro has taken off to the races extremely strong since its spring approval this year, surpassing market expectations by more than double
Eating protein first during meals, including healthy fats, and consuming plenty of fiber can naturally boost GLP-1 production in your body
With proper support and dosing adjustments, these effects usually resolve
CVOTs In response to FDA guidelines requiring the assessment of anti-diabetic therapeutics in relation to cardiovascular risk, several CVOTs have been performed